Gene: FRMD5

84978
-
FERM domain containing 5
protein-coding
15q15.3
Ensembl:ENSG00000171877 MIM:616309 Vega:OTTHUMG00000060475 UniprotKB:Q7Z6J6
NC_000015.10
PubMed
0   ANCO-SNPs
ND
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.037e-1 (AD)  6.428e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
LRRC8D0.873
DIP2C0.868
CEP970.865
PTK20.864
MTRR0.86
TTLL70.859
GNAI10.858
PXK0.855
TRAPPC100.853
UBE2G10.852

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.559
OR4F29-0.536
FOXL1-0.326
SIX1-0.305
FMO1-0.293
KLRB1-0.288
OR4F16-0.283
KIR2DL3-0.281
TTLL10-0.281
IL2RB-0.278

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of FRMD5 mRNA"19114083
C5116212-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Particulate Matter results in decreased expression of FRMD5 mRNA]28655636
C5116212-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Vehicle Emissions results in decreased expression of FRMD5 mRNA]28655636
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD5 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD5 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD5 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of FRMD5 mRNA26690555
D000082AcetaminophenAcetaminophen results in increased expression of FRMD5 mRNA22230336|2906747
D000082AcetaminophenAcetaminophen affects the expression of FRMD5 mRNA17562736
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of FRMD5 mRNA21641981
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of FRMD5 gene27153756
D000447AldehydesAldehydes results in increased expression of FRMD5 mRNA25014914
D000638AmiodaroneAmiodarone results in increased expression of FRMD5 mRNA19774075
D001151ArsenicArsenic affects the methylation of FRMD5 gene25304211
D001564Benzo(a)pyreneBenzo(a)pyrene affects the expression of FRMD5 mRNA21714911|2231617
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of FRMD5 mRNA26238291
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of FRMD5 mRNA"20382639
C006780bisphenol Abisphenol A affects the methylation of FRMD5 promoter27334623
C006780bisphenol Abisphenol A results in decreased expression of FRMD5 mRNA25181051
C018475butyraldehydebutyraldehyde results in increased expression of FRMD5 mRNA26079696
D002392Catechin[Catechin co-treated with Grape Seed Proanthocyanidins] results in decreased expression of FRMD5 mRNA24763279
D003042CocaineCocaine results in decreased expression of FRMD5 mRNA17898221
D019327Copper SulfateCopper Sulfate results in increased expression of FRMD5 mRNA19549813
D003471CuprizoneCuprizone results in increased expression of FRMD5 mRNA26577399
D016572CyclosporineCyclosporine results in increased expression of FRMD5 mRNA25562108
C089595cylindrospermopsincylindrospermopsin results in increased expression of FRMD5 mRNA24921660
D003907DexamethasoneDexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of FRMD5 mRNA]27941970
D004397FonofosFonofos results in increased methylation of FRMD5 promoter22847954
C511402Grape Seed Proanthocyanidins[Catechin co-treated with Grape Seed Proanthocyanidins] results in decreased expression of FRMD5 mRNA24763279
C051890irinotecanirinotecan analog results in decreased expression of FRMD5 mRNA18927307
D008727MethotrexateMethotrexate results in increased expression of FRMD5 mRNA24449571
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of FRMD5 mRNA28001369
C016599mono-(2-ethylhexyl)phthalatemono-(2-ethylhexyl)phthalate results in decreased expression of FRMD5 mRNA22401849
C523799MRK 003MRK 003 results in decreased expression of FRMD5 mRNA21169257
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of FRMD5 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of FRMD5 mRNA"25554681
C029938nickel sulfatenickel sulfate results in decreased expression of FRMD5 mRNA22714537
D010278ParathionParathion results in increased methylation of FRMD5 promoter22847954
D052638Particulate Matter2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Particulate Matter results in decreased expression of FRMD5 mRNA]28655636
D052638Particulate MatterParticulate Matter results in decreased expression of FRMD5 mRNA28655636
C046012pentanalpentanal results in increased expression of FRMD5 mRNA26079696
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD5 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of FRMD5 mRNA26272509
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of FRMD5 mRNA22714537
C005556propionaldehydepropionaldehyde results in increased expression of FRMD5 mRNA26079696
D011441PropylthiouracilPropylthiouracil results in decreased expression of FRMD5 mRNA24780913
D011794QuercetinQuercetin results in increased expression of FRMD5 mRNA21632981
C513635S-2-pentyl-4-pentynoic hydroxamic acidS-2-pentyl-4-pentynoic hydroxamic acid results in increased expression of FRMD5 mRNA21427059
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of FRMD5 mRNA25895662
C012568terbufosterbufos results in increased methylation of FRMD5 promoter22847954
C009495titanium dioxidetitanium dioxide results in decreased expression of FRMD5 mRNA23557971
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD5 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of FRMD5 mRNA24935251|2627250
C013320tris(2-butoxyethyl) phosphatetris(2-butoxyethyl) phosphate affects the expression of FRMD5 mRNA29024780
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD5 mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased expression of FRMD5 mRNA23179753|2627250
D014635Valproic AcidValproic Acid results in increased expression of FRMD5 mRNA23179753|2493525
D014635Valproic AcidValproic Acid results in increased methylation of FRMD5 gene29154799
D014635Valproic AcidValproic Acid affects the expression of FRMD5 mRNA17292431
D014635Valproic AcidValproic Acid results in increased expression of FRMD5 mRNA21427059
D001335Vehicle Emissions2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Vehicle Emissions results in decreased expression of FRMD5 mRNA]28655636
D001335Vehicle EmissionsVehicle Emissions results in decreased expression of FRMD5 mRNA28655636

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005178integrin binding-IDA25448675  
GO:0005515protein binding-IPI22846708  25448675  
GO:0008092cytoskeletal protein binding-IEA-  
GO:0019901protein kinase binding-IDA25448675  
GO ID GO Term Qualifier Evidence PubMed
GO:0030334regulation of cell migration-IMP22846708  
GO:0031032actomyosin structure organization-IBA21873635  
GO:0045785positive regulation of cell adhesion-IMP25448675  
GO:2000146negative regulation of cell motility-IMP25448675  
GO ID GO Term Qualifier Evidence PubMed
GO:0005856cytoskeleton-IBA21873635  
GO:0005912adherens junction-IDA22846708  
GO:0016021integral component of membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
29212247A six-mRNA signature model for the prognosis of head and neck squamous cell carcinoma. (2017 Nov 7)Guo WOncotarget
28332615Integrative variants, haplotypes and diplotypes of the CAPN3 and FRMD5 genes and several environmental exposures associate with serum lipid variables. (2017 Mar 23)Guo TSci Rep